About LYNX DX INC
Lynx Dx is a diagnostic testing company specializing in prostate cancer risk assessment, offering the MyProstateScore 2.0 (MPS2) urine test, which uses 18 gene transcripts to predict clinically significant prostate cancer. The company focuses on providing accurate, personalized, and flexible diagnostic tools for physicians and patients.
Prostate cancer risk assessment using a urine-based testAnalysis of 18 unique gene transcriptsIntegration of optional clinical risk factorsGeneration of individualized reportsAt-home sample collection for patients
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to LYNX DX INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.